Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651902 | 0.84 | TRPV4 (0.48) | EGLN2TRPV4CYP11B1CYP11B2AR | |
| SCHEMBL22684010 | 0.84 | TRPV4 (0.38) | EGLN2TRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL30432017 | 0.84 | TRPV4 (0.38) | EGLN2TRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL29533592 | 0.80 | AR (0.40) | EGLN2TRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL363348 | 0.80 | KHK (0.39) | TRPV4CYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL25202481 | 0.80 | KHK (0.39) | EGLN2TRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL1815433 | 0.80 | AR (0.40) | EGLN2TRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL152108 | 0.80 | EGLN2 (0.43) | EGLN2TRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL25871523 | 0.80 | CYP11B1 (0.37) | EGLN2TRPV4CYP11B1CYP11B2KDM4E | |
| SCHEMBL29546655 | 0.79 | CYP3A4 (0.47) | EGLN2TRPV4KDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3826722-B1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-12378249-B2 | Isoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12319698-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2025045058-A1 | COMPOUND ACTING AS ANDROGEN RECEPTOR ANTAGONIST | 中国药科大学 | 2025-03-06 | — | — | WO | disclosed |
| CN-112585132-B | Proteasome activity enhancing compounds | 优曼尼蒂公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | YUMANITY THERAPEUTICS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11560385-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| WO-2022254027-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2022-12-08 | — | — | WO | disclosed |
| US-20210253580-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3814338-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Proteostasis Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2473491-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| EP-0391591-B1 | Pyrimidine derivative and liquid crystal composition incorporating the same | SEIKO EPSON CORP (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-5200110-A | Electro-optical displays; heat resistance, dielectrics, low driving voltage, dielectrics | SEIKO EPSON CORPORATION (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0224001-B1 | ANTHRANILONITRILE DERIVATIVES AND RELATED COMPOUNDS AS USEFUL AGENTS FOR PROMOTING GROWTH, IMPROVING FEED EFFICIENCY, AND FOR INCREASING THE LEAN MEAT TO FAT RATIO OF WARM-BLOODED ANIMALS | AMERICAN CYANAMID COMPANY (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4863959-A | Anthranilonitrile derivatives as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0224001-A1 | Anthranilonitrile derivatives and related compounds as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378249-B2 | Isoquinoline compounds and uses thereof | HIPK1, HPGDS, IP6K1 | EGLN2 446/4885TRPV4 4701/4885CYP11B1 1472/4885 |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | EGLN2 245/4885TRPV4 4603/4885CYP11B1 2284/4885 |
| US-11560385-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | EGLN2 1545/4885TRPV4 4405/4885CYP11B1 2776/4885 |
| US-12319698-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | EGLN2 1545/4885TRPV4 4405/4885CYP11B1 2776/4885 |
| US-20210253580-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HIPK1, HPGDS, IP6K1 | EGLN2 446/4885TRPV4 4701/4885CYP11B1 1472/4885 |
| US-20230183256-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSME3, PSMC4 | EGLN2 1545/4885TRPV4 4405/4885CYP11B1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.